» Articles » PMID: 24819221

Differences in the Rate of Oestrogen-induced Apoptosis in Breast Cancer by Oestradiol and the Triphenylethylene Bisphenol

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 2014 May 14
PMID 24819221
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Purpose: Triphenylethylene (TPE)-like compounds were the first agents to be used in the treatment of metastatic breast cancer in postmenopausal women. Although structurally related to the anti-oestrogen, 4-hydroxytamoxifen, TPEs possess oestrogenic properties in fully oestrogenized breast cancer cells but do not induce apoptosis with short-term treatment in long-term oestrogen-deprived breast cancer cells. This study determined the differential effects of bisphenol, a TPE, on growth and apoptosis based on the modulation of the shape of the ligand-oestrogen receptor complex.

Experimental Approach: Apoptotic flow cytometric studies were used to evaluate apoptosis over time. Proliferation of the breast cancer cells was assessed using DNA quantification and cell cycle analysis. Real-time PCR was performed to quantify mRNA levels of apoptotic genes. Regulation of cell cycle and apoptotic genes was determined using PCR-based arrays.

Key Results: Bisphenol induced an up-regulation of cell cycle genes similar to those induced by 17β oestradiol (E2 ). Unlike the changes induced by E2 that occur after 24 h, the apoptosis evoked by bisphenol occurred after 4 days, with quantifiable apoptotic changes noted at 6 days. A prolonged up-regulation of endoplasmic reticulum stress and inflammatory stress response genes was observed with subsequent activation of apoptosis-related genes in the second week of treatment with bisphenol.

Conclusions And Implications: The bisphenol: ERα complex induces delayed biological effects on the growth and apoptosis of breast cancer cells. Both the shape of the complex and the duration of treatment control the initiation of apoptosis.

Citing Articles

Estrogen Receptor Complex to Trigger or Delay Estrogen-Induced Apoptosis in Long-Term Estrogen Deprived Breast Cancer.

Maximov P, Fan P, Abderrahman B, Curpan R, Jordan V Front Endocrinol (Lausanne). 2022; 13:869562.

PMID: 35360069 PMC: 8960923. DOI: 10.3389/fendo.2022.869562.


Turning scientific serendipity into discoveries in breast cancer research and treatment: a tale of PhD students and a 50-year roaming tamoxifen team.

Jordan V Breast Cancer Res Treat. 2021; 190(1):19-38.

PMID: 34398352 PMC: 8557169. DOI: 10.1007/s10549-021-06356-8.


Pharmacology and Molecular Mechanisms of Clinically Relevant Estrogen Estetrol and Estrogen Mimic BMI-135 for the Treatment of Endocrine-Resistant Breast Cancer.

Abderrahman B, Maximov P, Curpan R, Hanspal J, Fan P, Xiong R Mol Pharmacol. 2020; 98(4):364-381.

PMID: 32788222 PMC: 7491312. DOI: 10.1124/molpharm.120.000054.


The Structure-Function Relationship of Angular Estrogens and Estrogen Receptor Alpha to Initiate Estrogen-Induced Apoptosis in Breast Cancer Cells.

Maximov P, Abderrahman B, Hawsawi Y, Chen Y, Foulds C, Jain A Mol Pharmacol. 2020; 98(1):24-37.

PMID: 32362585 PMC: 7294906. DOI: 10.1124/mol.120.119776.


Estrogen-Induced Apoptosis in Breast Cancers Is Phenocopied by Blocking Dephosphorylation of Eukaryotic Initiation Factor 2 Alpha (eIF2α) Protein.

Sengupta S, Sevigny C, Bhattacharya P, Jordan V, Clarke R Mol Cancer Res. 2019; 17(4):918-928.

PMID: 30655322 PMC: 8922434. DOI: 10.1158/1541-7786.MCR-18-0481.


References
1.
Wolf D, Jordan V . A laboratory model to explain the survival advantage observed in patients taking adjuvant tamoxifen therapy. Recent Results Cancer Res. 1993; 127:23-33. DOI: 10.1007/978-3-642-84745-5_4. View

2.
Jordan V, Schafer J, Levenson A, Liu H, Pease K, Simons L . Molecular classification of estrogens. Cancer Res. 2001; 61(18):6619-23. View

3.
Jordan V . Selective estrogen receptor modulation: concept and consequences in cancer. Cancer Cell. 2004; 5(3):207-13. DOI: 10.1016/s1535-6108(04)00059-5. View

4.
Obiorah I, Jordan V . Scientific rationale for postmenopause delay in the use of conjugated equine estrogens among postmenopausal women that causes reduction in breast cancer incidence and mortality. Menopause. 2013; 20(4):372-82. PMC: 3740456. DOI: 10.1097/GME.0b013e31828865a5. View

5.
Anderson G, Chlebowski R, Aragaki A, Kuller L, Manson J, Gass M . Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012; 13(5):476-86. PMC: 3412626. DOI: 10.1016/S1470-2045(12)70075-X. View